Prospects for research in haemophilia with real‐world data—An analysis of German registry and secondary data.

Introduction and aim: Open questions in haemophilia, such as effectiveness of innovative therapies, clinical and patient‐reported outcomes (PROs), epidemiology and cost, await answers. The aim was to identify data attributes required and investigate the availability, appropriateness and accessibility of real‐world data (RWD) from German registries and secondary databases to answer the aforementioned questions. Methods: Systematic searches were conducted in BIOSIS, EMBASE and MEDLINE to identify non‐commercial secondary healthcare databases and registries of patients with haemophilia (PWH). Inclusion of German patients, type of patients, data elements—stratified by use in epidemiology, safety, outcomes and health economics research—and accessibility were investigated by desk research. Results: Screening of 676 hits, identification of four registries [national PWH (DHR), national/international paediatric (GEPARD, PEDNET), international safety monitoring (EUHASS)] and seven national secondary databases. Access was limited to participants in three registries and to employees in one secondary database. One registry asks for PROs. Limitations of secondary databases originate from the ICD‐coding system (missing: severity of haemophilia, presence of inhibitory antibodies), data protection laws and need to monitor reliability. Conclusion: Rigorous observational analysis of German haemophilia RWD shows that there is potential to supplement current knowledge and begin to address selected policy goals. To improve the value of existing RWD, the following efforts are proposed: ethical, legal and methodological discussions on data linkage across different sources, formulation of transparent governance rules for data access, redefinition of the ICD‐coding, standardized collection of outcome data and implementation of incentives for treatment centres to improve data collection. [ABSTRACT FROM AUTHOR]